Next Treatments
Back to Eczema

orismilast

TypePill StagePhase 2 Latest updateMar 7, 2025Phase 2 results posted

What stands out

  • Blocks PDE4 to lower inflammation in the body
Derived from NCT05469464 · MedlinePlus: Difamilast Topical · This is a summary of public records for informational purposes only. It is not medical advice.

Results

Trial: NCT05469464
Percent Change From Baseline in EASI Score at Week 16After 16 weeks

Lower scores mean less severe eczema.

Placebo Tablets55 people
50% lower
Orismilast Modified Release Tablets 20 mg58 people
55% lower
Orismilast Modified Release Tablets 30 mg61 people
52% lower
Orismilast Modified Release Tablets 40 mg59 people
61% lower
040%80%
5points
more of a drop on average on Orismilast Modified Release Tablets 20 mg than on placebo.
The sponsor’s 95% confidence range is 9 points less to 18 more.
2points
more of a drop on average on Orismilast Modified Release Tablets 30 mg than on placebo.
The sponsor’s 95% confidence range is 12 points less to 16 more.
11points
more of a drop on average on Orismilast Modified Release Tablets 40 mg than on placebo.
The sponsor’s 95% confidence range is 3 points less to 25 more.
NCT05469464 · Ages 18+ · Results posted Mar 2025 · This is a summary of trial data for informational purposes only. It is not medical advice.
What is EASI?
  • EASI stands for Eczema Area and Severity Index.
  • The EASI is a tool to measure the severity of clinical signs and the percentage of affected body surface area (BSA) in patients with atopic dermatitis (AD).As this trial registered it · NCT05469464 (the full definition is there)
Why this trial?

orismilast has one trial with posted results, and NCT05469464 compared the drug with placebo on a result this page charts.

History

Earliest recorded event: Jul 11, 2022. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

Sources

Trials